258 related articles for article (PubMed ID: 35949105)
1. Combinations of chemo-, immuno-, and gene therapies using nanocarriers as a multifunctional drug platform.
Hopkins C; Javius-Jones K; Wang Y; Hong H; Hu Q; Hong S
Expert Opin Drug Deliv; 2022 Oct; 19(10):1337-1349. PubMed ID: 35949105
[TBL] [Abstract][Full Text] [Related]
2. Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy.
Pérez-Herrero E; Fernández-Medarde A
Eur J Pharm Biopharm; 2015 Jun; 93():52-79. PubMed ID: 25813885
[TBL] [Abstract][Full Text] [Related]
3. Nanocarriers overcoming biological barriers induced by multidrug resistance of chemotherapeutics in 2D and 3D cancer models.
Petrikaite V; D'Avanzo N; Celia C; Fresta M
Drug Resist Updat; 2023 May; 68():100956. PubMed ID: 36958083
[TBL] [Abstract][Full Text] [Related]
4. Targeted multifunctional lipid-based nanocarriers for image-guided drug delivery.
Koning GA; Krijger GC
Anticancer Agents Med Chem; 2007 Jul; 7(4):425-40. PubMed ID: 17630918
[TBL] [Abstract][Full Text] [Related]
5. Actively targeted nanocarriers for drug delivery to cancer cells.
Biffi S; Voltan R; Bortot B; Zauli G; Secchiero P
Expert Opin Drug Deliv; 2019 May; 16(5):481-496. PubMed ID: 30955393
[TBL] [Abstract][Full Text] [Related]
6. Nanocarrier-based Drug Delivery System for Cancer Therapeutics: A Review of the Last Decade.
Sohail M; Guo W; Li Z; Xu H; Zhao F; Chen D; Fu F
Curr Med Chem; 2021; 28(19):3753-3772. PubMed ID: 33019919
[TBL] [Abstract][Full Text] [Related]
7. Nanocarriers for Anticancer Drug Targeting: Recent Trends and Challenges.
Dahiya S; Dahiya R; Hernández E
Crit Rev Ther Drug Carrier Syst; 2021; 38(6):49-103. PubMed ID: 34587429
[TBL] [Abstract][Full Text] [Related]
8. Multifunctional and stimuli-responsive nanocarriers for targeted therapeutic delivery.
Majumder J; Minko T
Expert Opin Drug Deliv; 2021 Feb; 18(2):205-227. PubMed ID: 32969740
[TBL] [Abstract][Full Text] [Related]
9. Tumor-targeting glycol chitosan nanocarriers: overcoming the challenges posed by chemotherapeutics.
Choi Y; Lim S; Yoon HY; Kim BS; Kwon IC; Kim K
Expert Opin Drug Deliv; 2019 Aug; 16(8):835-846. PubMed ID: 31343904
[No Abstract] [Full Text] [Related]
10. Nanocarrier-Based Therapeutics and Theranostics Drug Delivery Systems for Next Generation of Liver Cancer Nanodrug Modalities.
Ruman U; Fakurazi S; Masarudin MJ; Hussein MZ
Int J Nanomedicine; 2020; 15():1437-1456. PubMed ID: 32184597
[TBL] [Abstract][Full Text] [Related]
11. Targeting cancer cells in the tumor microenvironment: opportunities and challenges in combinatorial nanomedicine.
Linton SS; Sherwood SG; Drews KC; Kester M
Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2016; 8(2):208-22. PubMed ID: 26153136
[TBL] [Abstract][Full Text] [Related]
12. Specific targeting cancer cells with nanoparticles and drug delivery in cancer therapy.
Raj S; Khurana S; Choudhari R; Kesari KK; Kamal MA; Garg N; Ruokolainen J; Das BC; Kumar D
Semin Cancer Biol; 2021 Feb; 69():166-177. PubMed ID: 31715247
[TBL] [Abstract][Full Text] [Related]
13. Chemo-drug Controlled-release Strategies of Nanocarrier in the Development of Cancer Therapeutics.
Liu Y; Ou H; Pei X; Jiang B; Ma Y; Liu N; Wen C; Peng C; Hu X
Curr Med Chem; 2021; 28(31):6307-6322. PubMed ID: 32503398
[TBL] [Abstract][Full Text] [Related]
14. Nanocarrier-mediated drugs targeting cancer stem cells: an emerging delivery approach.
Malhi S; Gu X
Expert Opin Drug Deliv; 2015 Jul; 12(7):1177-201. PubMed ID: 25601619
[TBL] [Abstract][Full Text] [Related]
15. Extracellularly activated nanocarriers: a new paradigm of tumor targeted drug delivery.
Gullotti E; Yeo Y
Mol Pharm; 2009; 6(4):1041-51. PubMed ID: 19366234
[TBL] [Abstract][Full Text] [Related]
16. Recent advances in delivery of drug-nucleic acid combinations for cancer treatment.
Li J; Wang Y; Zhu Y; Oupický D
J Control Release; 2013 Dec; 172(2):589-600. PubMed ID: 23624358
[TBL] [Abstract][Full Text] [Related]
17. Metallic nanoparticles as drug delivery system for the treatment of cancer.
Neha Desai ; Momin M; Khan T; Gharat S; Ningthoujam RS; Omri A
Expert Opin Drug Deliv; 2021 Sep; 18(9):1261-1290. PubMed ID: 33793359
[TBL] [Abstract][Full Text] [Related]
18. Stimuli-sensitive nanopreparations for combination cancer therapy.
Jhaveri A; Deshpande P; Torchilin V
J Control Release; 2014 Sep; 190():352-70. PubMed ID: 24818767
[TBL] [Abstract][Full Text] [Related]
19. Recent advances in herbal combination nanomedicine for cancer: delivery technology and therapeutic outcomes.
Anwar DM; El-Sayed M; Reda A; Fang JY; Khattab SN; Elzoghby AO
Expert Opin Drug Deliv; 2021 Nov; 18(11):1609-1625. PubMed ID: 34254868
[No Abstract] [Full Text] [Related]
20. Nano-immunotherapy: Overcoming tumour immune evasion.
Guevara ML; Persano F; Persano S
Semin Cancer Biol; 2021 Feb; 69():238-248. PubMed ID: 31883449
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
